peptide that is isolated only from human urine. This study describes the development of a URO-specific antibody and a RIA for URO in urine. At present, there is no commonly available URO-specific antibody. We produced a URO-specific antibody without cross-reactivity with atrial natriuretic peptide (ANP) analogs by immunization of rabbits with the URO (95-126) peptide and subsequent purification of the resulting URO antiserum with affinity chromatography with CNBr-activated Sepharose 4B. The urine samples were ethanolextracted before assay. The CVs were 6.7% (intraassay) and 14.1% (interassay). This study reports the circadian urinary excretion of URO in 24 healthy subjects with seven sampling periods per 24 h. 3 URO belongs to the natriuretic peptide family and is identical in structure to the circulating 28-amino acid human atrial natriuretic peptide (ANP) (99 -126), with addition of four amino acids (ThrAla-Pro-Arg) at the NH 2 terminus. URO is measurable in human urine, but not in human plasma, suggesting that URO is a peptide synthesized and secreted in the kidney [2] . Studies have shown that apparently URO is cleaved in the kidney from a prohormone identical to the ANP prohormone found in the atria [3] . Probably URO is synthesized in the distal cortical nephron and secreted luminally to have its paracrine action downstream in the nephron at the inner medullary collecting duct, where the peptide inhibits Na ϩ entry through the amiloride-sensitive sodium channels via the guanylate cyclase-coupled receptors previously described for ANP [4, 5] .
INDEXING TERMS: atrial natriuretic peptide • sodium • diuresis • circadian rhythm Urodilatin (URO) (95-126) is a 32-amino acid peptide isolated from human urine that was characterized by Forssmann et al. [1] in 1988. 3 URO belongs to the natriuretic peptide family and is identical in structure to the circulating 28-amino acid human atrial natriuretic peptide (ANP) (99 -126), with addition of four amino acids (ThrAla-Pro-Arg) at the NH 2 terminus. URO is measurable in human urine, but not in human plasma, suggesting that URO is a peptide synthesized and secreted in the kidney [2] . Studies have shown that apparently URO is cleaved in the kidney from a prohormone identical to the ANP prohormone found in the atria [3] . Probably URO is synthesized in the distal cortical nephron and secreted luminally to have its paracrine action downstream in the nephron at the inner medullary collecting duct, where the peptide inhibits Na ϩ entry through the amiloride-sensitive sodium channels via the guanylate cyclase-coupled receptors previously described for ANP [4, 5] .
Studies have shown that urinary excretion of URO correlates closely with variations in salt excretion in humans [6, 7] , and that urinary excretion of URO may have a closer correlation with urinary sodium loss than plasma ANP [8] . URO seems to be an important natriuretic peptide, but numerous questions about the role of URO in human physiology and pathophysiology are still open. Therefore, a reliable specific assay for measuring URO in urine is needed to investigate further the biological role of URO. Drummer et al. [9] developed a UROspecific RIA involving a polyclonal URO antibody specific for the four N-terminal residues of URO. This specific URO antibody was raised in rabbits by immunizing them with the short N-terminal fragment of human URO containing the four amino acids by which URO differs from ANP. This URO antibody is not commonly available and the immune respose that is correlated to immunogens with low molecular mass often is poor; therefore we report here the development and purification of a URO antibody raised in rabbits immunized with the whole 32-amino acid URO peptide containing the immunogenic ring structure.
The aims of the present study were (a) to raise a URO antibody in rabbits by immunization with the synthetic URO peptide of 32 amino acids and to purify the resulting URO antiserum with CNBr-activated Sepharose 4B affinity chromatography to a degree without cross-reactivity with ANP analogs, (b) to develop a specific and sensitive RIA for measuring URO-like immunoreactivity (irURO) in human urine, and (c) to investigate if the excretion rate of URO in urine has a circadian variation in healthy volunteers. immunization procedure Aliquots of 160 g each (100 L) of the URO-thyroglobulin complex were emulsified with 100 L of incomplete Freund's adjuvant and injected subcutaneously into the backs of white rabbits. Immunizations were performed every 2 weeks, and after day 42, a booster injection was given at 4-week intervals. Blood was drawn 12 days after each booster injection [10] .
Materials and Methods reagents

affinity chromatography
As the resulting polyclonal URO antibodies cross-reacted with ANP, CNBr-activated Sepharose 4B affinity chromatography was used for purification of the rabbit antiserum [11] . In short, three different columns of CNBr-activated Sepharose-4B were coupled to BSA, ANP, and URO, respectively. Freeze-dried CNBr-activated Sepharose-4B was suspended in ice-cold HCl (1 mmol/L). The gel was washed and reswelled three times. It was then immediately transferred to a solution of the ligand, 30 mg of BSA, 1 mg of ANP, and 2 mg of URO dissolved in coupling buffer (0.1 mol/L NaHCO 3 containing 0.5 mol/L NaCl, pH 7-8). The three protein-gel suspensions were rotated end-over-end for 2 h at room temperature. After coupling, the solutions were transferred to a 0.2 mol/L glycine buffer, pH 8.0, standing overnight at 4°C, to block remaining active groups on the gel. The three ligandSepharose conjugates were packed in rheodex columns. To remove excess uncoupled ligand, the absorbent was washed alternately with high-and low-pH buffer solutions (coupling buffer followed by 0.1 mol/L acetate buffer, pH 4, containing 0.5 mol/L NaCl). Finally, 10 mmol/L Tris buffer, pH 7.5, was used to wash away the blocking agent. The rabbit serum was applied to the BSA column with free flow; the unbound fraction of the serum was transferred to the ANP column, and subsequently the nonadsorbed amount was applied to the URO column. A glycine buffer (0.1 mol/L, pH 2.5) was used as the eluting agent on the URO column. The eluted fractions were collected in tubes containing a small amount of 1 mol/L Tris buffer, pH 8.0. The fraction with the highest protein content measured at wavelength 260 nm was selected, stored at Ϫ20°C, and investigated for URO-specific antibodies.
iodination procedure URO was iodinated by the Iodo-Gen method according to Salacinski et al. [12] with minor modifications [13] . In short, Iodo-Gen was dissolved in dichloromethane/trichloromethane (40 mg/L). Aliquots (150-L) of the IodoGen solution were evaporated by dry nitrogen atmosphere in cryotubes. Ten microliters of a solution containing 0.2 mg of synthetic URO per mL of 0.1 mol/L acetic acid was transferred to the Iodo-Gen tube and mixed with 100 L of 0.5 mol/L sodium phosphate buffer, pH 7.4, and 7 L of Na 125 I (25.9 MBq). The iodination reaction was allowed to run for 10 min. The solution was then applied to a DEAE-Sephadex A-25 column equilibrated with 0.1 mol/L sodium phosphate buffer, pH 7.4, which also was the eluting buffer. The fraction with peak radioactivity was selected and diluted with assay buffer. Aliquots of the URO tracer were stored at Ϫ20°C for up to 6 weeks.
sample extraction
Human urine samples were extracted by addition of absolute ethanol (1:1.5 dilution of samples) with subsequent centrifugation and lyophilization of the supernatant. Dried extracts were resuspended in assay buffer. 
high-performance liquid chromatography
The identity of the immunoreactive material in human urine was studied by HPLC. A HPLC system from Pharmacia LKB was used. Reversed-phase HPLC was performed on a C 18 column (250 ϫ 4.6 mm, 5 m) (The Separations Group, Hesperia, CA). Eluent A consisted of water with 1 g/L TFA and eluent B was a mixture of water:acetonitrile (20:80 by vol) with 1 g/L TFA. Eluent A (1000 mL/L) was applied for 2 min followed by 30 min of a linear gradient to 1000 mL/L eluent B with a resulting content of acetonitrile in the eluent ranging from 0 to 800 mL/L. The flow was 1 mL/min. Samples with synthetic URO and extracted human urine were dissolved in eluent A before injection.
healthy volunteers
Twenty four healthy volunteers, all men, with a mean age of 44 years, range 23-66 years, were studied during a 24-h period in the hospital. The inclusion criteria were: (a) healthy male volunteer, (b) age between 20 and 70 years, and (c) written informed consent to undergo the study. The exclusion criteria were: (a) clinical and (or) laboratory evidence of renal, hepatic, cardiovascular, endocrinological, allergic, infectious, or neoplastic disease; (b) history of bladder dysfunction; and (c) alcohol abuse. They received a standard hospital diet and a fluid intake of 1500 mL/m 2 per 24 h. The meals were given at 0730, 1200, and 1800 and there was no fluid intake during the night. The subjects were only in the supine position during the night, and only minimal activity was allowed during the daytime. Urine was collected in the following seven periods: 1500 -1800, 1800 -2100, 2100 -2400, 0000 -0700, 0700 -1000, 1000 -1300, and 1300 -1500. The subjects gave written informed consent, and the study was approved by the local Ethics Commitee.
Results antisera
Two of four rabbits produced detectable URO antibodies within 12 weeks after initial immunization. The antiserum from one rabbit was usable at a dilution of 1:2000, but this polyclonal URO antibody cross-reacted 25% with synthetic ANP (99 -126).
The polyclonal URO antibody was purified by CNBrSepharose affinity chromatography. The fraction eluting from the URO column with the highest protein concentration contained a highly specific URO antibody with a cross-reactivity of Ͻ0.1% with human ANP (99 -126) and human pro-ANP (31-67) (Fig. 1) . No cross-reactivity was observed with pro-ANP (1-30), BNP, CNP, Aldo, AVP, and cGMP. The purified antiserum was used at a final dilution of 1:4000. Scatchard plot analysis [14] of the purified antiserum exposed a homogeneous antibody population. The antibody is characterized by a K of 1.05 ϫ 10 11 L/mol.
iodination of uro
Twenty three percent of the radioactive iodine was incorporated in the final tracer preparation. The specific activity of the iodized URO substance was 15.84 MBq/g, calculated by the self-displacement ability as described by Morris [15] . Approximately 0.47 mol of iodide/mol of URO was available during the iodination process. Assuming a specific activity of 647.5 GBq/mg Na 125 I and monoiodination of URO, it could be calculated that ϳ64% of the URO molecules in the tracer solution were labeled.
calibration curve
The RIA for URO was optimized. Reproducible calibration curves were obtained and a typical zero calibrator binding, 50% inhibitory dose (ID 50 ), and nonspecific binding was ϳ50%, 19 fmol/tube, and 7%, respectively. Nonspecific binding of [ 125 I]URO in human urine was ϳ4%, indicating that interference by substances in urine was not significant.
lower limit of detection
The lower limit of detection was 0.5 fmol/tube (P Ͻ0.05, paired test, n ϭ 12) with a 95% level of confidence, corresponding to a urine concentration of 7.5 pmol/L URO if 400 L of urine was extracted and resuspended in 600 L of assay buffer, using 100 L for assay. The amount of URO measured is a linear function of the volume of urine extract assayed in RIA. The y-axis intercept is not significantly different from zero as seen in Fig. 2 . The measurable irURO in urine extract diluted parallel to the calibration curve.
The immunoreactivity of URO in extracts (1:1.5 dilution with ethanol) from 300, 500, 750, and 1500 L of morning urine from five healthy subjects was the same (55.9 Ϯ 25.2, 52.6 Ϯ 23.7, 58.9 Ϯ 25.9, 54.8 Ϯ 28.5 pmol/L) (mean Ϯ SD). The proportion between the volume of urine and ethanol used in the extraction procedure seems to have important influence on the measured concentration of irURO.
Varying the ethanol volume between 0 and 500 L in the extraction of 500 L of urine (n ϭ 4) showed that irURO graduallly decreased from 114.5 pmol/L to 93.5 pmol/L. stability Urine samples (n ϭ 8) kept at room temperature for 24 h to 72 h before extraction did not show a decay of endogenous URO immunoreactive material. Storage of urine samples at Ϫ20°C for up to 3 months or repeated cycles (n ϭ 4) of freezing and thawing did not change the measured immunoreactivity of URO.
hplc identification of iruro from human urine extract HPLC tracing of 1 pmol of URO injected directly to the column eluted with a major peak after 17 min. HPLC tracing of 0.5 mL of ethanol-extracted human urine supplemented with 1 pmol of URO showed a major peak after 17 min and a small peak after 4 min. If human urine supplemented with 1 pmol of URO was stored at room temperature for 24 h, the elution profile showed that the majority of irURO eluted after 4 min and a minor part after 17 min. This early peak of irURO could represent a decomposition product of URO. The eluting pattern of ethanol-extracted human urine consisted of a major peak after 4 min and in addition two minor peaks after 12 min and 17 min. Thus, the identity of irURO in human urine extracts seems to have an elution profile identical to URO and a degradation product of URO.
reference values in healthy volunteers
The urinary URO excretion in 24 healthy adults during a 24-h study period with seven urine collections is illustrated in Fig. 3 . The excretion of URO did not change significantly during the 24 h, but there was a tendency towards a lower URO excretion rate in the urine collected from 0000 to 0700.
Discussion
A method allowing measurement of URO in human urine is of importance in assessing the physiological and pathophysiological roles of this natriuretic peptide. At present, there is no commonly available URO-specific antibody. We produced a URO-specific antibody by immunization of rabbits with the URO (95-126) peptide and subsequent purification of the resulting URO antiserum with affinity chromatography using CNBr-activated Sepharose 4B. The purified polyclonal URO antibody cross-reacted Ͻ0.1% with the ANP analogs. Thereby, we solved the difficulties inherent in the generation of a URO-specific antibody. Compared with the immunization procedure used by Drummer et al. [9] , we succeeded in developing a UROspecific antibody without using an immunogen with low molecular mass.
The immunoextracted rabbit antiserum contains one homogeneous population of antibodies against URO, indicated by linearity of the Scatchard plot. The affinity of the purified antibody population is approximately the same as the affinity of the URO-specific antibody developed by Drummer Problems associated with reduced sensitivity and nonspecific absorption have been described for ANP assays involving the charcoal procedure for separation of bound and free ligand [16] . In the present assay, the lowest nonspecific bound values (ϳ7%) were obtained when using a mixture of PEG and porcine ␥-globulin as carrier instead of PEG alone or dextran-coated charcoal. This is a simple, fast, cheap, and reproducible precipitation method [17] .
The Iodo-Gen method was chosen as Rasmussen et al. [13] reported about this simple and succesful iodination method for preparation of an ANP tracer without loss of immunoreactivity during iodination as described by Gutkowska et al. with the chloramine T method [18] . The method was reproducible in the present study.
The irURO in urine proved to be stable at room temperature for 72 h. Likewise, the present data showed no loss of irURO after prolonged storage at Ϫ20°C or by repeated cycles of freezing and thawing. In contrast, Drummer et al. [9] observed a significant decay of immunoreactive material if human urine samples were stored at room temperature. As well, conflicting data exist about the stability of ANP [19 -22] . An explanation of the unchanged concentration of irURO could be that the purified URO antibody cross-reacted also with a degradation product of URO generated during storage. This is supported by HPLC analyses that showed that the irURO in stored human urine had an elution profile identical to URO and a degradation product of URO.
The circadian study showed that the excretion rates of URO in urine were almost unchanged during day and night. Despite a tendency towards a lower URO excretion rate during the night, we did not find a significant circadian 24-h rhythm with minimal excretion rates during the night as indicated by Drummer et al. in their study with a small number of subjects [6] . The URO excretions, determined with the use of our specific RIA, were higher than indicated by Drummer et al. [6] and Kentsch et al. [23] , but in all three studies the excretion rates were in the range of 20 -200 fmol/min. The proportion between the amount of urine and ethanol used in the extraction procedure might have an important influence on the measured concentration of irURO.
In conclusion, the present combination of immunization of rabbits with the URO (95-126) peptide and subsequent purification of the resulting URO antiserum with CNBractivated Sepharose affinity chromatography was a simple way of producing a URO-specific antibody without cross-reactivity with ANP analogs. The RIA for URO demonstrated specificity and sensitivity for URO in human urine. The usefulness of the assay has been presented in the circadian study, and it seems to be convenient when a large number of clinical samples are to be assayed. Further studies are needed to elucidate the physiological significance of URO in urine under various physiological and pathological conditions.
